Zuclopenthixol
Classification: BATC code: N05AF05
Summary
Zuclopenthixol is an antipsychotic agent of the first generation that blocks dopamine D2-receptors. Sex differences regarding the antipsychotic effect or adverse events have not been reported.
Additional information
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of zuclopenthixol have been found.
Effects
No studies with a clinically relevant sex analysis regarding the antipsychotic effect of zuclopenthixol have been found.
Adverse effects
Publications reporting sex differences of zuclopenthixol regarding adverse effects were not found. However, a register based study in patients older than 65 years (179 men, 356 women) did not detect any sex difference regarding the risk of death with zuclopenthixol [1].
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Updated: 2020-08-28
Date of litterature search: 2019-07-20
References
- Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.] länk
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson